Potential targets and mechanisms of Di(2-ethylhexyl) phthalate exposure in inducing chronic kidney disease: a multimodal study integrating epidemiology, network toxicology, and Mendelian randomization.
Yihan Wang, Qi Liu, Xiaojun Li, Ruizhi Tan, Hong Li, Junming Fan, Jun Zhu, Li Wang
{"title":"Potential targets and mechanisms of Di(2-ethylhexyl) phthalate exposure in inducing chronic kidney disease: a multimodal study integrating epidemiology, network toxicology, and Mendelian randomization.","authors":"Yihan Wang, Qi Liu, Xiaojun Li, Ruizhi Tan, Hong Li, Junming Fan, Jun Zhu, Li Wang","doi":"10.1007/s00210-026-05972-9","DOIUrl":null,"url":null,"abstract":"<p><p>Di(2-ethylhexyl) phthalate (DEHP) is a widely used plasticizer present in numerous consumer and medical products and has been associated with adverse effects in multiple organ systems, including the kidney. Chronic kidney disease (CKD) is an increasing global health burden, yet the molecular targets potentially linking DEHP exposure to CKD remain incompletely understood. This study integrated epidemiological analysis, network toxicology, Mendelian randomization (MR), molecular docking, and molecular dynamics simulations to investigate potential molecular targets associated with DEHP exposure and CKD. Data from the National Health and Nutrition Examination Survey (NHANES) were used to examine the association between urinary DEHP metabolites and CKD. DEHP-related and CKD-related targets were subsequently integrated to identify shared targets, followed by PPI network analysis and expression-based evaluation to prioritize candidate genes. MR analysis was then performed to assess the association between genetically proxied candidate genes and CKD. Molecular docking was used to explore the potential interactions between DEHP and the prioritized proteins, and molecular dynamics simulations were performed to further evaluate the structural stability of the predicted DEHP-CTSK complex. Higher urinary DEHP metabolite levels were associated with a higher prevalence of CKD. Four candidate genes-CTSK, ABL1, BCL2L1, and CCND1-were prioritized based on network and expression-based analyses. Among these genes, genetically proxied CTSK showed a significant positive association with CKD in the primary MR analysis. Molecular docking showed favorable predicted docking scores for DEHP with the four candidate proteins, while molecular dynamics simulations supported the structural stability of the predicted DEHP-CTSK complex over 100 ns. These findings provide convergent epidemiological, genetic, and computational evidence supporting CTSK as a candidate molecular target for further investigation in the context of DEHP-associated renal injury.</p>","PeriodicalId":18876,"journal":{"name":"Naunyn-Schmiedeberg's archives of pharmacology","volume":" ","pages":""},"PeriodicalIF":4.0000,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Naunyn-Schmiedeberg's archives of pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00210-026-05972-9","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Di(2-ethylhexyl) phthalate (DEHP) is a widely used plasticizer present in numerous consumer and medical products and has been associated with adverse effects in multiple organ systems, including the kidney. Chronic kidney disease (CKD) is an increasing global health burden, yet the molecular targets potentially linking DEHP exposure to CKD remain incompletely understood. This study integrated epidemiological analysis, network toxicology, Mendelian randomization (MR), molecular docking, and molecular dynamics simulations to investigate potential molecular targets associated with DEHP exposure and CKD. Data from the National Health and Nutrition Examination Survey (NHANES) were used to examine the association between urinary DEHP metabolites and CKD. DEHP-related and CKD-related targets were subsequently integrated to identify shared targets, followed by PPI network analysis and expression-based evaluation to prioritize candidate genes. MR analysis was then performed to assess the association between genetically proxied candidate genes and CKD. Molecular docking was used to explore the potential interactions between DEHP and the prioritized proteins, and molecular dynamics simulations were performed to further evaluate the structural stability of the predicted DEHP-CTSK complex. Higher urinary DEHP metabolite levels were associated with a higher prevalence of CKD. Four candidate genes-CTSK, ABL1, BCL2L1, and CCND1-were prioritized based on network and expression-based analyses. Among these genes, genetically proxied CTSK showed a significant positive association with CKD in the primary MR analysis. Molecular docking showed favorable predicted docking scores for DEHP with the four candidate proteins, while molecular dynamics simulations supported the structural stability of the predicted DEHP-CTSK complex over 100 ns. These findings provide convergent epidemiological, genetic, and computational evidence supporting CTSK as a candidate molecular target for further investigation in the context of DEHP-associated renal injury.
期刊介绍:
Naunyn-Schmiedeberg''s Archives of Pharmacology was founded in 1873 by B. Naunyn, O. Schmiedeberg and E. Klebs as Archiv für experimentelle Pathologie und Pharmakologie, is the offical journal of the German Society of Experimental and Clinical Pharmacology and Toxicology (Deutsche Gesellschaft für experimentelle und klinische Pharmakologie und Toxikologie, DGPT) and the Sphingolipid Club. The journal publishes invited reviews, original articles, short communications and meeting reports and appears monthly. Naunyn-Schmiedeberg''s Archives of Pharmacology welcomes manuscripts for consideration of publication that report new and significant information on drug action and toxicity of chemical compounds. Thus, its scope covers all fields of experimental and clinical pharmacology as well as toxicology and includes studies in the fields of neuropharmacology and cardiovascular pharmacology as well as those describing drug actions at the cellular, biochemical and molecular levels. Moreover, submission of clinical trials with healthy volunteers or patients is encouraged. Short communications provide a means for rapid publication of significant findings of current interest that represent a conceptual advance in the field.